Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04047589
Other study ID # IUSCC-0690
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 8, 2019
Est. completion date February 28, 2020

Study information

Verified date August 2023
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to understand the preferences and barriers surrounding exercise of both the patients and oncologists within Indiana University Simon Cancer Center. This information will establish gaps in our current care and provide important information to guide future pilot interventions.


Description:

This descriptive, cross-sectional study will survey patients with a current or previous diagnosis of non-metastatic solid tumor malignancy who are being seen at the Indiana University Simon Cancer in Indianapolis, Indiana. Patients with active, incurable disease are excluded. Willing and eligible patients will complete a brief, 14 question survey while seen in the waiting room of the women's or multi-disciplinary clinics. We aim to survey 350 patients over a 12 month period. Patients will fill out the survey at only one point in time and no patient identifiers will be kept. During COVID-19 restrictions, we will also send out an electronic version of the survey to participants using the email address provided in their Cerner accounts. Responses will be captured by REDCAP and will remain anonymous and not linked to the patients' medical record or personal health information. The physician survey will be emailed to oncologist/hematologists practicing within IUSCC who see patients at least once per week. Physicians will receive a survey at only one point in time. The survey will be anonymous and no physician identifiers will be kept. Primary objective Estimate the proportion of patients with curable solid tumor malignancies seen at the Indiana University Simon Cancer Center who are meeting exercise recommendations for cancer survivors (more than 150 minutes per week of moderate or 75 minutes per week of vigorous activity). Secondary objectives - Assess patients' perceived barriers to exercise during cancer survivorship - Assess patients' preferences for receiving exercise recommendations - Assess oncologists' perceived barriers to making exercise recommendations - Assess oncologists' preferences for exercise and physical activity resources that could be provided by the cancer center


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date February 28, 2020
Est. primary completion date February 28, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Physician survey Any oncologist/hematologist practicing within IUSCC regularly providing care for patients with solid tumor malignancies (seeing patients one or more days per week in the multidisciplinary or women's clinics with solid tumor malignancies). Physicians providing care only for hematologic (multiple myeloma, leukemia, lymphoma, transplant) or benign disorders will be excluded. - Patient survey 1. Patients with a current or previous diagnosis of stage 0-III or curable solid tumor 2. Patients receiving any component of their medical oncologic care at IUSCC 3. Age = 18 years 4. Able to read and write English Exclusion Criteria: 1. Metastatic disease at the time of study participation 2. Inability to complete the survey

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Survey regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
Survey created at Indiana University to gain information regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations
Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations, and potential resources the cancer center might provide to help make effective exercise recommendations in the future

Locations

Country Name City State
United States Indiana University Melvin & Bren Simon Cancer Center Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients who meet exercise recommendations. Patients self-reporting more than 150 minutes per week of moderate physical activity OR more than 75 minutes per week of vigorous physical activity baseline
Secondary Patient Perceived barriers to exercise during cancer survivorship via pilot survey Investigator created survey with 14 items regarding demographics, cancer history, exercise habits, and exercise as part of cancer treatment Baseline
Secondary Patient preferences for receiving exercise recommendations via pilot survey Investigator created survey with 14 items regarding demographics, cancer history, exercise habits, and exercise as part of cancer treatment Baseline
Secondary Provider perceived barriers to making exercise recommendations via pilot survey Investigator created survey with 14 items regarding demographics, cancer speciality, exercise habits, and exercise recommendations to patients and patient exercise habits Baseline
Secondary Provider preferences for exercise and physical activity resources that could be provided by the cancer center via pilot survey Investigator created survey with 14 items regarding demographics, cancer speciality, exercise habits, and exercise recommendations to patients and patient exercise habits Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2